In this issue:
Leukaemia selection
Ibrutinib vs. ofatumumab in previously treated CLL
A comprehensive prognostic index for CLL
Targetable kinase-activating lesions in Ph-like ALL
Idelalisib for relapsed/ refractory CLL
QT interval prolongation with arsenic trioxide
Lymphoma selection
Rituximab maintenance in FL
A prospective study of MGZL
Restaging bone marrow in PET-negative DLBCL
Dose-intense ABVD without consolidation RT in advanced HL
R-CHOP ±bevacizumab in previously untreated DLBCL
Please login below to download this issue (PDF)